Primary Navigation for the CDC Website
CDC en Español
Vaccine Safety
divider
E-Mail Icon E-mail this page
Printer Friendly Icon Printer-friendly version
divider
 Vaccine Safety Basics
bullet Information for Parents
bullet Why It's Important to Monitor Vaccine Safety
bullet How Vaccines Are Tested and Monitored
bullet Common Questions
bullet Vaccine Safety Concerns
bullet History of Vaccine Safety

 Public Health Activities
bullet Vaccine Adverse Event Reporting System (VAERS)
bullet Publications
bullet Gardasil Vaccine Reports
bullet Intussusception after RotaTeq Vaccination
bullet Vaccine Safety Datalink (VSD) Project
bullet Clinical Immunization Safety Assessment (CISA) Network
bullet Brighton Collaboration
bullet Vaccine Technology
bullet Emergency Preparedness
bullet Publications
bullet Scientific Agenda
Get E-Mail Updates Get email updates
 

 

Quick Links

bullet HPV and HPV Disease Information
bullet HPV Vaccine Information
bullet Vaccine Safety Information
bullet HPV Questions and Answers
bullet FDA Center for Biologics Evaluation and Research
bullet To Report an Adverse Event in VAERS
bullet Related Information on Guillain-Barré Syndrome
bullet Information from FDA and CDC on Gardasil and its Safety

Reports of Health Concerns Following HPV Vaccination

HPV Vaccine Safety

The safety of the HPV vaccine was studied in 7 clinical trials before it was licensed. There were over 21,000 girls and women ages 9 through 26 in these clinical trials.

Since it was licensed, CDC and FDA have been closely monitoring the safety of the HPV vaccine. There are 3 systems used to monitor the safety of vaccines after they are licensed and being used in the U.S.  These systems can monitor side effects already known to be caused by vaccines as well as detect rare side effects that were not identified during a vaccine's clinical trials. The 3 systems are:

  • The Vaccine Adverse Event Reporting System (VAERS)--a useful early warning public health system that helps CDC and FDA detect possible side effects or adverse events following vaccination.


  • The Vaccine Safety Datalink (VSD) Project--a project between CDC and 8 health care organizations to study patterns in reports detected by VAERS and determine if a vaccine is causing a side effect.


  • The Clinical Immunization Safety Assessment (CISA) Network--a project between 6 academic centers in the U.S. which conduct research on adverse events that might be caused by vaccines.

Reports to VAERS Following HPV Vaccination

As of August 31, 2008, there have been 10,326 VAERS reports of adverse events following Gardasil vaccination in the United States. Of these reports, 94% were reports of events considered to be non-serious, and 6% were reports of events considered to be serious.

Based on all of the information we have today, CDC and FDA have determined that Gardasil is safe to use and effective in preventing 4 types of HPV. As with all approved vaccines, CDC and FDA will continue to closely monitor the safety of Gardasil. Any problems detected with this vaccine will be reported to health officials, healthcare providers, and the public, and needed action will be taken to ensure the public's health and safety.

Non-serious adverse event reports

VAERS defines non-serious adverse events as those other than hospitalization, death, permanent disability, and life-threatening illness.

The vast majority (94%) of the adverse events reports following Gardasil have been non-serious. Reports of non-serious adverse events after Gardasil vaccination have included fainting, pain and swelling at the injection site (the arm), headache, nausea and fever. Fainting is common after injections and vaccinations, especially in adolescents. Falls after fainting may sometimes cause serious injuries, such as head injuries, which can be easily prevented by keeping the vaccinated person seated for up to 15 minutes after vaccination.

Serious adverse event reports

VAERS defines serious adverse events as adverse events that involve hospitalization, death, permanent disability, and life-threatening illness. As with all VAERS reports, serious events may or may not have been caused by the vaccine.

All serious reports (6%) for Gardasil have been carefully analyzed by medical experts. Experts have not found a common medical pattern to the reports of serious adverse events reported for Gardasil that would suggest that they were caused by the vaccine. The following is a summary of the serious adverse event reports that were submitted to VAERS between June 8, 2006 and August 31, 2008.

Guillain-Barré Syndrome (GBS)

Guillain-Barré Syndrome (GBS) has been reported after vaccination with Gardasil. GBS is a rare disorder that causes muscle weakness. It occurs in 1-2 out of every 100,000 people in their teens. A number of infections can cause GBS. There has been no indication that Gardasil increases the rate of GBS in girls and women above the rate expected in the general population, whether or not they were vaccinated.

Blood Clots

People have reported blood clots after getting Gardasil. These clots have occurred in the heart, lungs, and legs. Most of these people had a risk of getting blood clots, such as taking oral contraceptives (the birth control pill).

Deaths

As of August 31, 2008, there have been 27 U.S. reports of death among females who have received the vaccine. There was no common pattern to the deaths that would suggest that they were caused by the vaccine. Of the 27 U.S. reports:

  • 3 reports were related to diabetes or heart failure
  • 3 reports were related to viral illnesses or meningitis (an infection in the brain)
  • 2 reports were related to drug use
  • 2 reports were related to blood clots
  • 5 reports are being evaluated (attempting to follow up/identify case)
  • 1 report is still under review or VAERS is still waiting for additional medical records, such as an autopsy report or death certificate
  • 1 report of seizure disorder (history of seizures)
  • 3 reports had an unknown cause of death
  • 7 reports that could not be evaluated because they did not have enough information to identify the person, or to verify that a person had died

Reports of adverse events after getting a vaccine can be submitted to VAERS by fax at 1-877-721-0366, online at https://secure.vaers.org/VaersDataEntryintro.htm, or by mail to Vaccine Adverse Event Reporting System, P.O. Box 1100, Rockville, MD 20849-1100.

Page last reviewed: October 21 2008
Page last updated: October 21, 2008
Content source: Immunization Safety Office

 

  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
Safer, Healthier People

Centers for Disease Control and Prevention
1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
Public Inquiries: 1-800-CDC-INFO (232-4636); 1-888-232-6348 (TTY)
USA.govDHHS Department of Health
and Human Services